Key Performance
More- Earnings Score: N/A
- Momentum Score: 34
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Fortrea to Attend Jefferies Global Healthcare Conference
Fortrea (Nasdaq: FTRE), a leading global contract research organization, announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The company reported strong first-quarter 2026 performance with a book-to-bill ratio of 1.15x, marking the third consecutive quarter above 1.1x.
06/02/2026, 6:00 PM • GlobeNewswire
Fortrea 推出 Fortrea Intelligent Technology™ 以助贊助商及研究中心進行更智能、更整合的試驗
Fortrea, a leading global clinical research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered solution designed to automate workflows and streamline clinical trial operations. Built on the Xcellerate® platform, FIT offers three pillars: full lifecycle trial management, data-driven foresight analytics, and AI-powered companion tools to improve trial speed, predictability, and quality for sponsors and research sites.
04/07/2026, 10:28 PM • GlobeNewswire
Fortrea, a leading global contract research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered suite of solutions designed to revolutionize clinical trial processes. FIT automates workflows, streamlines oversight, and improves productivity for investigators, clinical trial centers, and research teams. The platform builds on Fortrea's flagship Xcellerate® platform and incorporates AI and machine learning to analyze complex patterns, generate predictive signals, and reduce manual tasks while enabling faster decision-making and risk management.
04/07/2026, 10:28 PM • GlobeNewswire
Fortrea 推出 Fortrea Intelligent Technology™，助力申办方和研究中心开展更智能、更协同的临床试验
Fortrea, a leading global clinical research organization, launched Fortrea Intelligent Technology (FIT), an AI-driven solution suite designed to transform clinical trial operations. FIT automates workflows, streamlines oversight, and provides real-time insights to sponsors, research sites, and study teams. Built on the Xcellerate® platform, the solution features three pillars: full lifecycle management, foresight analytics, and AI-powered companion tools to accelerate trial delivery and improve quality.
04/07/2026, 10:28 PM • GlobeNewswire
Grabar Law Office is investigating potential securities fraud and fiduciary breaches for several publicly traded companies, alleging misleading statements and undisclosed business risks that potentially harmed shareholders.
12/12/2025, 2:37 PM • GlobeNewswire
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea announced granting 245,000 restricted stock units (RSUs) to two newly hired employees, with vesting occurring in three equal annual installments starting December 10, 2026.
12/10/2025, 6:00 PM • GlobeNewswire
Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.
12/02/2025, 12:39 PM • GlobeNewswire
Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
Fortrea has completed a debt tender offer, purchasing $75.7 million of its outstanding 7.500% Senior Secured Notes due 2030, reducing the principal outstanding from $570 million to $494.3 million.
11/24/2025, 7:00 AM • GlobeNewswire
Law firm Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for four publicly traded companies, alleging misleading statements and undisclosed material facts that impacted investor interests.
11/15/2025, 8:22 AM • GlobeNewswire
Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call
Fortrea, a global contract research organization, will release its third quarter 2025 financial results on November 5, 2025, with a conference call scheduled at 8:00 am ET to review the results and conduct a Q&A session.
10/15/2025, 7:00 AM • GlobeNewswire
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea announced granting 75,000 restricted stock units (RSUs) to a newly hired employee, with vesting occurring in three equal annual installments starting September 12, 2026.
09/12/2025, 4:15 PM • GlobeNewswire
Fortrea (FTRE) Q2 Revenue Jumps 7%
Fortrea Holdings reported Q2 2025 revenue of $710.3 million, beating analyst estimates by 12.5%. Despite positive revenue growth and improved adjusted earnings, the company faced challenges including a significant goodwill impairment and a book-to-bill ratio below target.
08/06/2025, 5:21 PM • The Motley Fool
Fortrea Reports Second Quarter 2025 Results
Fortrea reported Q2 2025 revenues of $710.3 million, with a GAAP net loss of $374.9 million, primarily due to a non-cash goodwill impairment charge. The company raised its 2025 revenue guidance and welcomed new CEO Anshul Thakral.
08/06/2025, 6:30 AM • GlobeNewswire
Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations
Fortrea has appointed Tracy Krumme as senior vice president of investor relations, succeeding Hima Inguva. Krumme brings over three decades of experience in investor relations and capital markets across life sciences and healthcare sectors.
08/05/2025, 6:00 PM • GlobeNewswire
A class action lawsuit has been filed against Fortrea Holdings, alleging the company overstated revenue projections and business prospects following its spin-off from Labcorp in 2023, resulting in significant stock price decline.
07/30/2025, 8:10 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.